Blood Brain Barrier Market (3rd Edition): Industry Trends and Global Forecasts, till 2035
Description
Blood Brain Barrier Market (3rd Edition): Industry Trends and Global Forecasts, till 2035
The Blood Brain Barrier Market is valued at USD 36 million in 2024 growing at a CAGR of 49% during the forecast period 2024-2035.
The focus of blood-brain barrier drugs and technologies is to address the challenges posed by the selective nature of the blood-brain barrier, enabling therapeutic agents to reach the brain directly. Recent years have seen increased research and investment to understand and overcome these challenges, driven by rising incidences of neurological diseases like Alzheimer's and Parkinson's. This trend is expected to drive demand for therapies that bypass the blood-brain barrier, fostering innovation and expanding the market in this area. Innovations include drug delivery systems, nanoparticles, and medical devices aimed at enhancing treatment efficacy for neurological disorders by improving drug transport across the blood-brain barrier.
According to a study by the World Health Organization (WHO), diseases affecting the central nervous system (CNS) such as Alzheimer’s disease, brain cancer, multiple sclerosis, Parkinson’s disease, and stroke have a significant unmet need for effective treatments. Neurological disorders are the second leading cause of death and the foremost cause of disability worldwide. In 2021, it was reported that nearly 3.4 billion people globally suffer from CNS disorders, with over 6 million people living with Alzheimer’s, a figure expected to nearly double by 2050. In the US, nearly one million people are affected by Parkinson’s disease, with approximately 90,000 new diagnoses annually. Extensive research and development efforts have yielded a variety of versatile blood-brain barrier technologies designed to enhance the permeability of the barrier or improve the brain-penetrating capabilities of pharmacological treatments. These advancements have attracted numerous new players to the field, suggesting significant growth potential in the years ahead.
Currently, the blood-brain barrier market is largely driven by technology licensing activities, as drug developers collaborate with platform providers to advance their therapeutic pipelines.
Key Market Segments
Type of Molecule
- Small Molecules
- Biologics
- Multiple Sclerosis
- Amyotrophic Lateral Sclerosis
- Mucopolysaccharidosis Type II (Hunter Syndrome)
- Leptomeningeal Carcinomatosis
- Mucopolysaccharidosis Type III A (Sanfilippo Syndrome A)
- Oral
- Intravenous
- Neurodegenerative Disorders
- Lysosomal Storage Disorders
- Neuro-Oncology Disorders
- North America
- Europe
- Asia-Pacific
- Rest of the World
- This chapter begins with an overview of the blood-brain barrier, discussing its importance in light of the increasing prevalence of neurological disorders. It covers various strategies for delivering drugs to the central nervous system (CNS), including both invasive and non-invasive techniques. The chapter also delves into the complexities of penetrating the blood-brain barrier and delivering drugs effectively to the CNS, highlighting the associated challenges.
- The chapter offers a comprehensive introduction to essential concepts concerning the structure of the human brain, its components, and their roles within the central nervous system (CNS). It extensively covers both invasive and non-invasive methods utilized for drug delivery to the CNS. Additionally, it provides a detailed overview of the blood-brain barrier, tracing its historical development and emphasizing its crucial role in facilitating effective drug delivery amid the rising incidence of neurological disorders. The chapter further explores prominent strategies employed to develop drugs and technologies capable of crossing the blood-brain barrier or circumventing it. Finally, it addresses the primary challenges associated with utilizing blood-brain barrier penetration technologies to enhance drug delivery efficiency to the CNS.
- The overview encompasses the current market status of technologies designed to penetrate the blood-brain barrier, providing details on various parameters. These include the development status (commercialized and under development), underlying technology principles (methods for drug delivery, biological approaches, physical techniques, etc.), types of pharmacological molecules compatible with blood-brain barrier penetration (biologics, small molecules, oligonucleotides, etc.), targeted disease indications, patent types, and licensing activities. The overview also profiles technology developers, detailing their establishment year, company size (in terms of workforce), and geographical location.
- Detailed overview of the current market landscape of blood-brain barrier penetrating therapies that are approved or currently being evaluated in clinical trials, featuring a detailed analysis based on relevant parameters, such as stage of development (approved, phase III, phase II, phase I, IND-enabling, pre-clinical and discovery), type of molecule (biologics, small molecules and other molecules), affiliated BBB penetration, route of administration (intranasal, intravenous, oral, subcutaneous and transmucosal) target disease indication and therapeutic area (neurodegenerative disorders, lysosomal storage disorders, neuro oncology disorders, oncological disorders, infectious diseases, pain disorders, autoimmune disorders, CNS disorders, cerebrovascular disorders and others). Additionally, the chapter includes an overview on the landscape of BBB penetrating therapy developers, presenting a detailed analysis based on several relevant parameters, such as year of establishment, company size (based on employee count), location of headquarters and most active players (in terms of the number of therapies).
- Comprehensive company profiles of prominent technology developers (shortlisted based on the following criteria: companies having more than three drugs (being developed using proprietary BBB technologies) in preclinical / clinical phase of development) in this domain, featuring an overview of the company, technology portfolio, product portfolio and recent developments and future outlook.
- A detailed analysis of company competitiveness in the field of blood-brain barrier technologies is conducted based on key parameters. These include developer attributes such as experience duration, company size, and development status. Additionally, the analysis assesses technology strengths, focusing on factors like the types of pharmacological molecules compatible with blood-brain barrier penetration, availability of patent protection, number of collaborations, number of drugs developed, and the highest phase of development achieved.
- This section provides a broad overview of the operational principles underlying prevalent approaches in the development of technologies aimed at penetrating the blood-brain barrier. These approaches include receptor-mediated transcytosis (RMT), which encompasses methods like bispecific antibodies and molecular trojan horse delivery via direct coupling or nanocarriers, strategies to enhance blood-brain barrier permeability, passive diffusion methods, and emerging techniques such as cell-penetrating peptides, macrocycles, and organ-on-a-chip technology.
- An in-depth examination of partnerships within the blood-brain barrier industry is conducted, considering various parameters. These include the year of partnership establishment, partnership type, compatibility of pharmacological molecules, therapeutic area, partner type, and identification of the most active participants based on the number of partnerships formed. Additionally, the analysis covers the regional distribution of partnership activities occurring in this domain from the period prior to 2018 through March 2024.
- This chapter provides a comprehensive exploration of the deal structures found in various types of technology licensing agreements within this field. It includes specifics on the rights pertaining to product ownership, associated royalties, upfront payments, and other contractual terms and conditions among industry stakeholders. The discussion is supported by detailed analysis based on key parameters such as the year of agreement, type of licensing agreement, the most active participants (in terms of the number of licensing agreements), the most popular technologies involved (in terms of the number of licensing agreements), and geographic considerations.
- This analysis focuses on the funding and investments directed towards companies involved in the development of technologies and drugs for blood-brain barrier penetration. It encompasses various sources such as venture capital financing, funds raised through IPOs and subsequent offerings, grants, and debt financing. The detailed examination covers funding events occurring between 2020 and March 2024, emphasizing the increasing interest shown by the venture capital community and other strategic investors in this market.
- This chapter provides a comprehensive analysis of patents filed or granted in the field of the blood-brain barrier since 2018. It examines several parameters including the year of patent publication, geographical distribution, CPC symbols, prominent players based on the number of patents filed or granted, and the type of organizations involved. Additionally, the chapter includes detailed patent benchmarking and valuation analysis, spotlighting leading patents based on the number of citations they have received.
- A strategic analysis showcasing the predominant drug development strategies adopted by a majority of drug developers with clinical candidates in this field. The analysis aims to assist stakeholder companies in enhancing their current drug development approaches to expedite the advancement of their lead drug candidates.
- A comprehensive 3D bubble chart illustrating the market potential of prevalent CNS disorders, prioritized by the number of blood-brain barrier (BBB) penetrant drugs in development. The chart considers metrics such as approved drugs, pipeline drugs, and the target patient population. It also features an in-depth discussion on epidemiological insights, causes, symptoms, ongoing development of BBB penetrant drugs for each specific disease, existing treatment options, and details of drugs already available on the market for each respective indication.
- A compilation of over 240 drug developers focusing on Alzheimer’s disease and Parkinson’s disease, identified as potential partners for providers of blood-brain barrier penetration technologies. These developers have been selected based on criteria including their organizational strength (such as company size and years of experience in the field), the robustness and maturity of their pipelines (in terms of the number of drugs and their developmental stages), targeted indications, types of molecules used, routes of administration, and mechanisms of action.
- Detailed analysis of the factors that can affect the growth of blood-brain barrier market. It also features identification and analysis of key drivers, potential restraints, emerging opportunities, and existing challenges.
- Comprehensive market forecast analysis to estimate the existing market size and future opportunity for global blood-brain barrier penetrating therapies market over the next decade. Based on multiple parameters, such as likely adoption trends and through primary validations, we have provided an informed estimate on the market evolution during the forecast period 2024-2035. The report also features the likely distribution of the current and forecasted opportunity within the global blood-brain barrier penetrating therapies market. Further, in order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.
- Comprehensive projections of the current and future blood-brain barrier penetrating therapies market across different types of molecules, such as small molecules and biologics.
- Comprehensive projections of the current and future blood-brain barrier penetrating therapies market across various routes of administration, such as oral and intravenous.
- Detailed projections of the current and future blood-brain barrier penetrating therapies market across different target disease indications, such as multiple sclerosis, mucopolysaccharidosis type II (hunter syndrome), amyotrophic lateral sclerosis, leptomeningeal carcinomatosis and mucopolysaccharidosis type III A (sanfilippo syndrome A).
- Detailed projections of the current and future blood-brain barrier penetrating therapies market across various therapeutic areas, such as neurodegenerative disorders, lysosomal storage disorders and neuro-oncology disorders.
- Detailed projections of the current and future blood-brain barrier penetrating therapies market across various key geographical regions, such as North America, Europe and Asia-Pacific and Rest of the World.
- Details pertaining to the sales forecast for approved / phase III drugs in the BBB penetrating therapies market.
- The report offers market leaders and newcomers valuable insights into revenue estimations for both the overall market and its sub-segments.
- Stakeholders can utilize the report to enhance their understanding of the competitive landscape, allowing for improved business positioning and more effective go-to-market strategies.
- The report provides stakeholders with a pulse on the Blood Brain Barrier Market, furnishing them with essential information on significant market drivers, barriers, opportunities, and challenges.
- ICBI
- Denali Therapeutics
- JCR Pharmaceuticals
- Cyclenium Pharma
- Lauren Sciences
- biOasis Technologies
- Ossianix
- Angiochem
- Genervon Biopharmaceuticals
- NEUWAY Pharma
- Tranquis Therapeutics
- CERES BRAIN Therapeutics
- Nanomerics
- Reglagene
Table of Contents
- 1. Preface
- 1.1 Introduction
- 1.2. Market Share Insights
- 1.3. Key Market Insights
- 1.4. Report Coverage
- 1.5. Key Questions Answered
- 1.6. Chapter Outlines
- 2. Research Methodology
- 2.1. Chapter Overview
- 2.2. Research Assumptions
- 2.3. Project Methodology
- 2.4. Forecast Methodology
- 2.5. Robust Quality Control
- 2.6. Key Market Segmentations
- 2.7. Key Considerations
- 2.7.1. Demographics
- 2.7.2. Economic Factors
- 2.7.3. Government Regulations
- 2.7.4. Supply Chain
- 2.7.5. Covid Impact
- 2.7.6. Market Access
- 2.7.7. Healthcare Policies
- 2.7.8. Industry Consolidation
- 3. Economic And Other Project Specific Considerations
- 3.1. Chapter Overview
- 3.2. Market Dynamics
- 3.2.1. Time Period
- 3.2.1.1. Historical Trends
- 3.2.1.2. Current And Future Estimates
- 3.2.2. Currency Coverage And Foreign Exchange Rates
- 3.2.2.1. Major Currencies Affecting The Market
- 3.2.2.2. Factors Affecting Currency Fluctuations And Foreign Exchange Rates
- 3.2.2.3. Impact Of Foreign Exchange Rate Volatility On The Market
- 3.2.2.4. Strategies For Mitigating Foreign Exchange Risk
- 3.2.3. Trade Policies
- 3.2.3.1. Impact Of Trade Barriers On The Market
- 3.2.3.2. Strategies For Mitigating The Risks Associated With Trade Barriers
- 3.2.4. Recession
- 3.2.4.1. Historical Analysis Of Past Recessions And Lessons Learnt
- 3.2.4.2. Assessment Of Current Economic Conditions And Potential Impact On The Market
- 3.2.5. Inflation
- 3.2.5.1. Measurement And Analysis Of Inflationary Pressures In The Economy
- 3.2.5.2. Potential Impact Of Inflation On The Market Evolution
- 4. Executive Summary
- 4.1. Chapter Overview
- 5. Introduction
- 5.1. Chapter Overview
- 5.2. Structure Of The Human Brain
- 5.3. Growing Burden Of Neurological Disorders
- 5.4. Strategies For Drug Delivery To The Cns
- 5.4.1. Invasive Techniques
- 5.4.1.1. Systemic Administration Of Therapeutics
- 5.4.1.2. Direct Administration Of Therapeutics
- 5.4.1.3. Intracerebral Devices And Implants
- 5.4.2. Non-invasive Techniques / Approaches
- 5.4.2.1. Liposomes
- 5.4.2.2. Exosomes
- 5.4.2.3. Prodrugs
- 5.4.2.4. Nanoparticles And Microspheres
- 5.4.2.5. Novel Formulations And Conjugates
- 5.4.3. Chemical Delivery Systems
- 5.5. Blood-brain Barrier
- 5.5.1. Key Historical Milestones
- 5.5.2. Structure And Key Components
- 5.5.3. Key Functions
- 5.6. Strategies For Drug Delivery Across The Blood-brain Barrier
- 5.6.1. Increasing Permeability By Temporary Disruption Of The Blood-brain Barrier
- 5.6.2. Pharmacological Strategies To Facilitate Transport Across The Blood-brain Barrier
- 5.7. Challenges Associated With Bbb Penetration And Cns Drug Delivery
- 5.8. Concluding Remarks
- 6. Market Landscape: Non-invasive Blood Brain Barrier Penetration Technologies
- 6.1. Chapter Overview
- 6.2. Non-invasive Blood-brain Barrier Penetration Technologies: Overall Market Landscape
- 6.2.1. Analysis By Status Of Development
- 6.2.2. Analysis By Technology Principle
- 6.2.3. Analysis By Compatible Pharmacological Molecule
- 6.2.4. Analysis By Type Of Patent
- 6.2.5. Analysis By Licensing Activity
- 6.3. Non-invasive Blood-brain Barrier Penetration Technology Providers: Overall Market Landscape
- 6.3.1. Analysis By Year Of Establishment
- 6.3.2. Analysis By Company Size
- 6.3.3. Analysis By Location Of Headquarters
- 7. Market Landscape: Blood-brain Barrier Penetrating Therapies
- 7.1. Chapter Overview
- 7.2. Blood-brain Barrier Penetrating Therapies: Overall Market Landscape
- 7.2.1. Analysis By Stage Of Development
- 7.2.2. Analysis By Type Of Molecule
- 7.2.3. Analysis By Affiliated Blood-brain Barrier Penetration Technology
- 7.2.4. Analysis By Route Of Administration
- 7.2.5. Analysis By Target Disease Indication
- 7.2.6. Analysis By Therapeutic Area
- 7.3. Blood-brain Barrier Penetrating Therapy Developers: Overall Market Landscape
- 7.3.1. Analysis By Year Of Establishment
- 7.3.2. Analysis By Company Size
- 7.3.3. Analysis By Location Of Headquarters
- 7.3.4. Most Active Developers: Analysis By Number Of Therapies
- 8. Company Profiles
- 8.1. Chapter Overview
- 8.2. Companies Based In North America
- 8.2.1. Angiochem
- 8.2.1.1. Company Overview
- 8.2.1.2. Technology Overview
- 8.2.1.3. Product Portfolio
- 8.2.1.4. Recent Developments And Future Outlook
- 8.2.2. Bioasis Technologies
- 8.2.2.1. Company Overview
- 8.2.2.2. Technology Overview
- 8.2.2.3. Product Portfolio
- 8.2.2.4. Recent Developments And Future Outlook
- 8.2.3. Denali Therapeutics
- 8.2.3.1. Company Overview
- 8.2.3.2. Technology Overview
- 8.2.3.3. Product Portfolio
- 8.2.3.4. Recent Developments And Future Outlook
- 8.2.4. Icb International
- 8.2.4.1. Company Overview
- 8.2.4.2. Technology Overview
- 8.2.4.3. Product Portfolio
- 8.2.4.4. Recent Developments And Future Outlook
- 8.2.5. Lauren Sciences
- 8.2.5.1. Company Overview
- 8.2.5.2. Technology Overview
- 8.2.5.3. Product Portfolio
- 8.2.5.4. Recent Developments And Future Outlook
- 8.3. Companies Based In Europe
- 8.3.1. Cyclenium Pharma
- 8.3.1.1. Company Overview
- 8.3.1.2. Technology Overview
- 8.3.1.3. Product Portfolio
- 8.3.1.4. Recent Developments And Future Outlook
- 8.3.2. Neuway Pharma
- 8.3.2.1. Company Overview
- 8.3.2.2. Technology Overview
- 8.3.2.3. Product Portfolio
- 8.3.2.4. Recent Developments And Future Outlook
- 8.3.3. Ossianix
- 8.3.3.1. Company Overview
- 8.3.3.2. Technology Overview
- 8.3.3.3. Product Portfolio
- 8.3.3.4. Recent Developments And Future Outlook
- 8.4. Companies Based In Asia-pacific
- 8.4.1. Jcr Pharmaceuticals
- 8.4.1.1. Company Overview
- 8.4.1.2. Technology Overview
- 8.4.1.3. Product Portfolio
- 8.4.1.4. Recent Developments And Future Outlook
- 9. Technology Competitiveness Analysis
- 9.1. Chapter Overview
- 9.2. Assumptions And Key Parameters
- 9.3. Methodology
- 9.4. Non-invasive Blood-brain Barrier Penetration Technologies: Competitiveness Analysis
- 9.4.1.1. Non-invasive Blood-brain Barrier Penetration Technologies Developed By Players Based In North America
- 9.4.1.2. Non-invasive Bbb Penetration Technologies Developed By Players Based In Europe And Asia-pacific
- 10. Non-invasive Bbb Penetration Technologies: Popular Approaches
- 10.1. Chapter Overview
- 10.2. Receptor Mediated Transcytosis (Rmt)
- 10.2.1. Types Of Target Receptors
- 10.2.1.1. Diphtheria Toxin Receptor
- 10.2.1.2. Insulin Receptor And Insulin-like Growth Factor Receptor
- 10.2.1.3. Low Density Lipoprotein Receptor-related Proteins (Lrp 1 And Lrp 2)
- 10.2.1.4. Transferrin Receptor
- 10.2.2. Types Of Rmt Approaches
- 10.2.2.1. Bispecific Antibody-based Approach
- 10.2.2.2. Molecular Trojan Horse-based Approach
- 10.2.2.2.1. Important Considerations For Designing Molecular Trojan Horses
- 10.2.2.2.2. Considerations For Designing A Trojan Horse Liposome (Thl)
- 10.2.2.2.3. Popular Conjugation Strategies
- 10.2.2.2.3.1. Direct Coupling Approach
- 10.2.2.2.3.2. Nanoparticles-based Approach
- 10.3. Increasing The Permeability Of The Bbb
- 10.3.1. Use Of Ultrasound Waves
- 10.3.2. Use Of High-frequency Electric Field
- 10.4. Passive Diffusion
- 10.5. Novel Approaches
- 10.5.1. Cell Penetrating Peptides
- 10.5.2. Macrocycles
- 10.5.3. Organ-on-a-chip Technology
- 11. Partnerships And Collaborations
- 11.1. Chapter Overview
- 11.2. Partnership Models
- 11.3. Non-invasive Bbb Technologies And Drugs: Partnerships And Collaborations
- 11.3.1. Analysis By Year Of Partnership
- 11.3.2. Analysis By Type Of Partnership
- 11.3.3. Analysis By Year And Type Of Partnership
- 11.3.4. Analysis By Type Of Partner
- 11.3.5. Analysis By Focus Area Of Partnership
- 11.3.6. Analysis By Type Of Molecule
- 11.3.7. Most Active Players: Analysis By Number Of Partnerships
- 11.3.8. Analysis By Geography
- 11.3.8.1. Local And International Agreements
- 11.3.8.2. Intercontinental And Intracontinental Agreements
- 12. Recent Licensing Agreements Analysis
- 12.1. Chapter Overview
- 12.2. Licensing Agreements: Importance In Pharmaceutical Industry
- 12.3. Types Of Licensing Agreements
- 12.3.1. Out-licensing Agreements
- 12.3.2. In-licensing Agreements
- 12.4. Components Of Licensing Agreements
- 12.5. Recent Examples Of Bbb Related Technology And Therapy Licensing Agreements
- 12.5.1. Analysis By Year Of Agreement
- 12.5.2. Analysis By Type Of Licensing Agreement
- 12.5.3. Most Active Players: Analysis By Number Of Licensing Agreements
- 12.5.4. Most Popular Technologies: Analysis By Number Of Licensing Agreements
- 12.5.5. Analysis By Geography
- 12.5.5.1. Local And International Licensing Agreements
- 12.5.5.2. Intercontinental And Intracontinental Licensing Agreements
- 13. Funding And Investment Analysis
- 13.1. Chapter Overview
- 13.2. Types Of Funding
- 13.3. Non-invasive Bbb Penetration Drugs And Technologies: Funding And Investments
- 13.3.1. Analysis By Year Of Investment
- 13.3.2. Analysis By Amount Invested
- 13.3.3. Analysis By Type Of Funding
- 13.3.4. Analysis Of Amount Invested By Type Of Funding
- 13.3.5. Analysis By Year Of Investment And Type Of Funding
- 13.3.6. Analysis By Type Of Compatible Pharmacological Molecule
- 13.3.7. Most Active Players: Analysis By Number Of Instances
- 13.3.8. Most Active Players: Analysis By Amount Raised
- 13.3.9. Most Active Investors: Analysis By Number Of Instances
- 13.3.10. Analysis By Geography
- 14. Patent Analysis
- 14.1. Chapter Overview
- 14.2. Scope And Methodology
- 14.3. Blood-brain Barrier Penetration Technologies And Drugs: Patent Analysis
- 14.3.1. Analysis By Patent Application Year
- 14.3.2. Analysis By Patent Publication Year
- 14.3.3. Analysis Of Granted Patents And Patent Applications By Publication Year
- 14.3.4. Analysis By Patent Jurisdiction
- 14.3.5. Analysis By Cpc Symbols
- 14.3.6. Analysis By Type Of Applicant
- 14.3.7. Leading Industry Players: Analysis By Number Of Patents
- 14.3.8. Leading Non-industry Players: Analysis By Number Of Patents
- 14.3.9. Leading Patent Assignees: Analysis By Number Of Patents
- 14.4. Patent Benchmarking Analysis
- 14.4.1. Analysis By Patent Characteristics
- 14.5. Patent Valuation
- 14.5.1. Leading Patents By Number Of Citations
- 15. Drug Development: Chessboard Strategy Analysis
- 15.1. Chapter Overview
- 15.2. Scope And Methodology
- 15.3. Strategy Adopted For Late-stage Drug Candidates
- 15.3.1. Izcargo / Jr-141 / Pabinafusp Alfa (Jcr Pharmaceuticals)
- 15.3.2. Ux-111 / Abo-102 (Ultragenyx)
- 15.3.3. Ang1005 / Paclitaxel Trevatide (Angiochem)
- 15.3.4. Anx005 (Annexon Biosciences)
- 15.3.5. Sar-442168 / Prn2246 (Sanofi)
- 15.4. Concluding Remarks
- 16. Market Potential For Key Neurological Disorders
- 16.1. Chapter Overview
- 16.2. Market Potential For Key Neurological Disorders
- 16.3. Methodology And Key Parameters
- 16.4. Key Neurological Disorders
- 16.4.1. Alzheimer’s Disease
- 16.4.1.1. Epidemiology
- 16.4.1.2. Symptoms
- 16.4.1.3. Current Treatment Options
- 16.4.1.3.1. Interventional Therapies
- 16.4.1.3.2. Non-interventional Therapies
- 16.4.1.4. Bbb Penetrating Drugs For Alzheimer’s Disease
- 16.4.1.5. Market Potential For Alzheimer’s Disease
- 16.4.2. Brain Cancer
- 16.4.2.1. Epidemiology
- 16.4.2.2. Symptoms
- 16.4.2.3. Current Treatment Options
- 16.4.2.3.1. Surgery
- 16.4.2.3.2. Radiation Therapy
- 16.4.2.3.3. Systemic Therapy
- 16.4.2.4. Bbb Penetrating Drugs For Brain Cancer
- 16.4.2.5. Market Potential For Brain Cancer
- 16.4.3. Multiple Sclerosis
- 16.4.3.1. Epidemiology
- 16.4.3.2. Symptoms
- 16.4.3.3. Current Treatment Options
- 16.4.3.3.1. Treatment For Attacks
- 16.4.3.3.2. Treatments To Modify Progression
- 16.4.3.3.3. Interferons
- 16.4.3.4. Bbb Penetrating Drugs For Multiple Sclerosis
- 16.4.3.5. Market Potential For Multiple Sclerosis
- 16.4.4. Parkinson’s Disease
- 16.4.4.1. Epidemiology
- 16.4.4.2. Symptoms
- 16.4.4.3. Current Treatment Options
- 16.4.4.3.1. Pharmacological Management Of Parkinson’s Disease
- 16.4.4.3.2. Non-pharmacological Management Of Parkinson’s Disease
- 16.4.4.3.3. Management Of Parkinson’s Disease Using Dietary Supplements
- 16.4.4.4. Bbb Penetrating Drugs For Parkinson’s Disease
- 16.4.4.5. Market Potential For Parkinson’s Disease
- 17. Likely Partner Analysis
- 17.1. Chapter Overview
- 17.2. Scoring Criteria And Key Assumptions
- 17.3. Scope And Methodology
- 17.4. Potential Strategic Partners For Blood-brain Barrier Technology Providers
- 17.4.1. Likely Partners In North America
- 17.4.2. Likely Partners In Europe
- 17.4.3. Likely Partners In Asia-pacific And Rest Of The World
- 18. Market Impact Analysis
- 18.1. Chapter Overview
- 18.2. Market Drivers
- 18.3. Market Restraints
- 18.4. Market Opportunities
- 18.5. Market Challenges
- 18.6. Conclusion
- 19. Global Blood-brain Barrier Penetrating Therapies Market
- 19.1. Chapter Overview
- 19.2. Key Assumptions And Methodology
- 19.3. Global Blood-brain Barrier Penetrating Therapies Market, 2024-2035
- 19.3.1. Scenario Analysis
- 19.3.1.1. Conservative Scenario
- 19.3.1.2. Optimistic Scenario
- 19.4. Key Market Segmentations
- 20. Blood-brain Barrier Penetrating Therapies Market, By Type Of Molecule
- 20.1. Chapter Overview
- 20.2. Key Assumptions And Methodology
- 20.3. Blood-brain Barrier Penetrating Therapies Market: Distribution By Type Of Molecule, 2024, 2029 And 2035
- 20.3.1. Blood-brain Barrier Penetrating Therapies Market For Biologics: Forecasted Estimates (2024-2035)
- 20.3.2. Blood-brain Barrier Penetrating Therapies Market For Small Molecule: Forecasted Estimates (2026-2035)
- 20.3. Data Triangulation And Validation
- 21. Blood-brain Barrier Penetrating Therapies Market, By Route Of Administration
- 21.1. Chapter Overview
- 21.2. Key Assumptions And Methodology
- 21.3. Blood-brain Barrier Penetrating Therapies Market: Distribution By Route Of Administration, 2024 And 2035
- 21.3.1. Blood-brain Barrier Penetrating Therapies Market For Intravenous Route Of Administration: Forecasted Estimates (2024-2035)
- 21.3.2. Blood-brain Barrier Penetrating Therapies Market For Oral Route Of Administration: Forecasted Estimates (2026-2035)
- 21.4. Data Triangulation And Validation
- 22. Blood-brain Barrier Penetrating Therapies Market, By Target Disease Indication
- 22.1. Chapter Overview
- 22.2. Key Assumptions And Methodology
- 22.3. Blood-brain Barrier Penetrating Therapies Market: Distribution By Target Indication, 2024, 2029 And 2035
- 22.3.1. Blood-brain Barrier Penetrating Therapies Market For Mucopolysaccharidosis Type Ii (Hunter Syndrome): Forecast Estimates (2024-2035)
- 22.3.2. Blood-brain Barrier Penetrating Therapies Market For Multiple Sclerosis: Forecast Estimates (2026-2035)
- 22.3.3. Blood-brain Barrier Penetrating Therapies Market For Amyotrophic Lateral Sclerosis: Forecast Estimates (2028-2035)
- 22.3.4. Blood-brain Barrier Penetrating Therapies Market For Leptomeningeal Carcinomatosis: Forecast Estimates (2026-2035)
- 22.3.5. Blood-brain Barrier Penetrating Therapies Market For Mucopolysaccharidosis Type Iii A (Sanfilippo Syndrome A): Forecast Estimates (2028-2035)
- 22.4. Data Triangulation And Validation
- 23. Blood-brain Barrier Penetrating Therapies Market, By Therapeutic Area
- 23.1. Chapter Overview
- 23.2. Key Assumptions And Methodology
- 23.3. Blood-brain Barrier Penetrating Therapies Market: Distribution By Therapeutic Area, 2024, 2029 And 2035
- 23.3.1. Blood-brain Barrier Penetrating Therapies Market For Lysosomal Storage Disorders: Forecast Estimates (2024-2035)
- 23.3.2. Blood-brain Barrier Penetrating Therapies Market For Neurodegenerative Disorders: Forecast Estimates (2026-2035)
- 23.3.3. Blood-brain Barrier Penetrating Therapies Market For Neuro-oncology Disorders: Forecast Estimates (2026-2035)
- 23.4. Data Triangulation And Validation
- 24. Blood-brain Barrier Penetrating Therapies Market, By Key Geographical Regions
- 24.1. Chapter Overview
- 24.2. Key Assumptions And Methodology
- 24.3. Blood-brain Barrier Penetrating Therapies Market: Distribution By Key Geographical Regions, 2024, 2029 And 2035
- 24.3.1. Blood-brain Barrier Penetrating Therapies Market In North America: Forecasted Estimates (2026-2035)
- 24.3.2. Blood-brain Barrier Penetrating Therapies Market In Europe: Forecasted Estimates (2028-2035)
- 24.3.3. Blood-brain Barrier Penetrating Therapies Market In Asia-pacific And Rest Of The World: Forecasted Estimates (2024-2035)
- 24.4. Data Triangulation And Validation
- 25. Blood-brain Barrier Penetrating Therapies Market, Sales Forecast Of Drugs
- 25.1. Chapter Overview
- 25.2. Key Assumptions And Methodology
- 25.3. Commercialized Blood-brain Barrier Penetrating Therapies: Sales Forecast
- 25.3.1. Izcargo / Jr-141 / Pabinafusp Alfa Sales Forecast
- 25.4. Phase Iii Blood-brain Barrier Penetrating Therapies: Sales Forecast
- 25.4.1. Ang1005 / Paclitaxel Trevatide / Grn1005 Sales Forecast
- 25.4.2. Sar-442168 / Prn2246 Sales Forecast
- 25.4.3. Ux-111 / Abo-102 Sales Forecast
- 25.5. Phase Ii/Iii Blood-brain Barrier Penetrating Therapies: Sales Forecast
- 25.5.1. Dnl310 / Etv:ids Sales Forecast
- 25.5.2. Dnl343 Sales Forecast
- 26. Conclusion
- 27. Executive Insights
- 27.1. Chapter Overview
- 27.2. Innovative California Biosciences International (Icbi)
- 27.2.1. Company Snapshot
- 27.2.2. Interview Transcript: Ram Bhatt, Chief Executive Officer, Chairman And Founder
- 27.3. Ossianix
- 27.3.1. Company Snapshot
- 27.3.2. Interview Transcript: Frank S Walsh, Chief Executive Officer And Founder
- 27.4. 2-bbb
- 27.4.1. Company Snapshot
- 27.4.2. Interview Transcript: Pieter Gaillard, Chief Executive Officer And Co-founder
- 27.5. Armagen
- 27.5.1. Company Snapshot
- 27.5.2. Interview Transcript: Mathias Schmidt, Chief Executive Officer
- 27.6. Bioasis Technologies
- 27.6.1. Company Snapshot
- 27.6.2. Interview Transcript: Rob Hutchison, Chief Executive Officer
- 27.7. Cyclenium Pharma
- 27.7.1. Company Snapshot
- 27.7.2. Interview Transcript: Mark L Peterson, Chief Operating Officer
- 27.8. Sagetis Biotech
- 27.8.1. Company Snapshot
- 27.8.2. Interview Transcript: Xavier Rivero, Chief Operating Officer
- 27.9. Carthera
- 27.9.1. Company Snapshot
- 27.9.2. Interview Transcript: Carole Desseaux, Head Of Clinical Affairs
- 27.10. Vect-horus
- 27.10.1. Company Snapshot
- 27.10.2. Interview Transcript: Jamal Temsamani, Head Of Drug Development
- 27.11. Wyss Institute, Harvard University
- 27.11.1. Organization Snapshot
- 27.11.2. Interview Transcript: Kevin Kit Parker, Professor
- 28. Appendix I: Tabulated Data
- 29. Appendix Ii: List Of Companies And Organizations
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
